Novartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients with Elevated Lp(a) and Established Cardiovascular Disease (CVD)
Phase 3negativepelacarsenNegative
AI Analysis
Summary
Novartis announced that pelacarsen failed to meet the primary endpoint in the Phase III Lp(a)HORIZON trial, which evaluated the drug for reducing cardiovascular events in patients with elevated Lp(a) and established CVD.
Clinical Trial Data
Phase
III
Primary Endpoint
Not Met
Outcome Details
did not meet primary endpoint of reducing risk of cardiovascular events
Importance:9/10
Sentiment:
-0.90
Phase_3_FailureCardiovascularLp(a)Clinical_Trial
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 4, 2026 10:09 PM